Trial NCT03864419

View at ClinicalTrials.gov 
Org. Study IDs: RG1001799
Secondary IDs: 10040 NCI-2019-01493 U028

Last trial update was posted on 2024-01-03

MeSH Interventions

Antibodies Antibodies, Monoclonal Antineoplastic Agents, Immunological Cyclophosphamide Daunorubicin Doxorubicin Etoposide Immunoglobulins Liposomal doxorubicin Methotrexate Podophyllotoxin Prednisone Rituximab Vincristine

MeSH Conditions

Burkitt Lymphoma Castleman Disease Lymphoma Lymphoma, B-Cell Lymphoma, Large B-Cell, Diffuse

Other Conditions

Diffuse Large B-Cell Lymphoma KSHV-associated Multicentric Castleman Disease

Stopping Reasons

Closed per SRC Low Accrual Policy

Limitations And Caveats

N/A

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID